The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines.
We work with members in England, Scotland, Wales and Northern Ireland.
Open letter to Secretary of State for International Trade on UK-India negotiations
The ABPI is one of 11 major cross-sector business groups that have written to Anne-Marie Trevelyan on talks between the UK and India
ABPI statement on biomarker testing
The ABPI commented in support of a call led by the Institute of Cancer Research (ICR) for all cancer patients to be offered genetic testing so they can get the best treatments available for them.
ABPI response to Life Sciences Competitiveness Indicators
The Government has today published Life Sciences Competitiveness Indicators, which provide data on the state of the life sciences sector in the UK.
ABPI welcomes first women's health strategy for England
The Government has today published the first women's health strategy for England, to tackle the gender health gap.
We are the only full-service trade association supporting members throughout the life-cycle of a branded medicines, from early discovery to patients.
We provide a wide range of services and support for our members. ABPI provides its members with a comprehensive monitoring package and regular updates.
In total, we have over 150 members: our Full Members represent many established research based pharmaceutical companies, our Research Affiliate Members are involved primarily in pharmaceutical research and development, whilst our General Affiliate members are organisations that work with the pharmaceutical industry in the UK.
We offer three different types of membership
Full Members represent many established research-based pharmaceutical companies.
Our Research Affiliate members are companies that carry out their business in the UK and are engaged in the research and/or development of medicines for human use, but which have no sales of such products in the UK.
General Affiliate membership is open to organisations with an interest in the pharmaceutical industry that operate in the UK.
We work for our members in two ways
Developing a compelling single voice for the prescription medicines and research & development industries
With stakeholders in the life-sciences and healthcare arena, to spread our messages to Government and other stakeholders for the benefit of patients
Working on behalf of member companies of all sizes
There is an opportunity for our member companies to be engaged with a wide range of industry activities.
Our Smaller Companies Board Sponsored Group is dedicated to supporting and addressing the specific issues and needs impacting this particular defined group of companies.
Two members of the Smaller Companies Board Sponsored Group also sit on the ABPI Board in order that this sector of industry is also reflected in wider ABPI considerations and approaches.
Adding value to our members
We offer additional value to our members through a range of proactive services in the form of up to date information and briefings, as well as a wide range of Industry data and resources to draw upon and utilise. The aim of this is to keep our members and their employees in touch with the latest issues and dynamics of the pharmaceutical industry in the UK.
Our expert teams can be drawn upon by all our members as required, to support and discuss your particular challenges, in addition to a wide range of information through our extranet to which all members are given access upon joining the ABPI.
There are many benefits of becoming a member of the ABPI and we are always happy to visit companies and discuss these in greater detail. If you would like to arrange a company visit, please contact the Membership Services – 0207 747 1414.